Philip C. Trackman, PhD
Boston University Henry M. Goldman School of Dental Medicine
Dept of Molecular & Cell Biology

PhD, Boston University

Research in Dr. Trackman’s laboratory is focused on the regulation of extracellular matrix accumulation in mineralized and non-mineralized normal tissues, and in pathologies in which extracellular matrix accumulation is affected. Studies, which utilize cell culture, animal models, and human tissues, encompass a wide range of experimental approaches derived from the disciplines of biochemistry, enzymology, cell biology, and quantitative biology. Goals of these studies are to obtain a greater understanding of the molecular and cellular basis for gingival overgrowth and other fibrotic diseases, and to understand mechanisms of osteopenia that occurs as a complication of type I diabetes. Recent important findings show that oral fibroblasts are resistant to the effects of certain inflammatory factors, and that this resistance contributes to the elevated expression of connective tissue growth factor (CCN2/CTGF). This growth factor, in turn, contributes to gingival overgrowth and oral fibrosis. In addition, the biological process of epithelial to mesenchymal transition has been identified as a contributor to gingival overgrowth. These understandings provide new avenues for therapeutic approaches to prevent and treat gingival overgrowth.

The mechanism by which lysyl oxidase acts as a tumor suppressor is under investigation. Dr. Trackman’s laboratory has made the novel discovery that the tumor suppressor function of lysyl oxidase resides in the propeptide (LOX-PP) region of a proenzyme precursor. This propeptide is released from the proenzyme by extracellular proteolytic processing, and the released propeptide inhibits growth of tumor cells and tumor formation. A focus of the laboratory is to identify mechanisms by which the lysyl oxidase propeptide can suppress tumor formation or tumor growth and tumor metastasis. A major target of LOX-PP was found to be the fibroblast growth factor receptor-1 (FGFR1). Intracellular targets are now under investigation. A polymorphism in LOX-PP was found to have impaired ability to suppress tumors in mice, and is a risk factor for breast cancer in estrogen receptor-negative breast tumors in humans. rLOX-PP is effective as an inhibitor of tumor growth in xenograft models. Dr. Trackman’s laboratory works on this project in collaboration with the laboratories of Dr. Gail Sonenshein (Tufts University School of Medicine) and Dr. Kathrin Kirsch of Boston University School of Medicine, Department of Biochemistry. The potential use of LOX-PP as a pharmacologic agent has been submitted and is pending in the U.S. patent office; and preclinical studies continue.

Director of Graduate Programs, Molecular & Cell Biology
Boston University Henry M. Goldman School of Dental Medicine
Molecular & Cell Biology

Research Assistant Professor
Boston University School of Medicine

Mentor for Graduate Medical Students
Boston University School of Medicine, Division of Graduate Medical Sciences

2013 PloS One: Academic Editor
1997-2011 Listed in Marquis Who’s Who in Science and Engineering
1981-1983 Brandeis University: American Cancer Society Postdoctoral Fellow
1977-1980 Boston University School of Medicine: Predoctoral NIH Traineeship
1975 American Chemical Society : Outstanding Senior Award

Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis
05/01/2018 - 04/30/2020 (Multi-PI)
PI: Philip C. Trackman, PhD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases

Biological Activit of Lysyl Oxidase Like-2 Inhibitors
04/01/2015 - 12/31/2017 (PI)

Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer
07/01/2014 - 06/30/2017 (PI)
NIH/National Institute of Dental & Craniofacial Research

Inhibited Intramembraneous Bone Healing in Diabetes
03/01/2009 - 01/31/2016 (PI)
NIH/National Institute of Dental & Craniofacial Research

Lysyl Oxidase Inhibition of Ras-Mediated Transformation
09/01/1999 - 04/30/2010 (Co-PI)
NIH/National Cancer Institute
5 R01 CA82742 10

Mechanisms of Mineralized Matrix Accumulation
02/01/1999 - 01/31/2004 (PI)
NIH/National Institute of Dental & Craniofacial Research
5 R01 DE12209 04

Screen Fibrogen anti-CTGF Antibodies for Blocking Activity
05/15/2001 - 05/14/2002 (PI)
FibroGen Inc

Phenotypic Reversion Requires Lysyl Oxidase mRNA
09/15/1998 - 09/14/2000 (PI)
NIH/National Institute of Dental & Craniofacial Research
5 R03 DE12425 02

Yr Title Project-Sub Proj Pubs
2018 Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis 1R21AR072748-01
2014 Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer 1R21DE023973-01A1 3
2013 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-10 28
2012 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-09 28
2011 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-08 28
2011 Growth Factors and Gingival Fibrosis 5R01DE011004-15 11
2010 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-07 28
2010 Growth Factors and Gingival Fibrosis 5R01DE011004-14 11
2009 Inhibited Intramembranous Bone Healing in Diabetes 2R01DE014066-06A2 28
2009 Growth Factors and Gingival Fibrosis 5R01DE011004-13 11
Showing 10 of 37 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. de la Cueva A, Emmerling M, Lim SL, Yang S, Trackman PC, Sonenshein GE, Kirsch KH. A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer. Carcinogenesis. 2018 Jul 03; 39(7):921-930.View Related Profiles. PMID: 29579155.
  2. Saxena D, Mahjour F, Findlay AD, Mously EA, Kantarci A, Trackman PC. Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes. J Dent Res. 2018 May 01; 22034518775971.View Related Profiles. PMID: 29787337.
  3. Herzog CR, Berzins DW, DenBesten P, Gregory RL, Hargreaves KM, Messer RLW, Mina M, Mooney MP, Paine ML, Phillips C, Presland RB, Quivey RG, Scannapieco FA, Sheridan JF, Svoboda KKH, Trackman PC, Walker MP, Walker SG, Wang CY, Hu JCC. Oral Sciences PhD Program Enrollment, Graduates, and Placement: 1994 to 2016. J Dent Res. 2018 May; 97(5):483-491. PMID: 29328868.
  4. Trackman PC. Functional importance of lysyl oxidase family propeptide regions. J Cell Commun Signal. 2018 Mar; 12(1):45-53. PMID: 29086201.
  5. Trackman PC, Bais MV. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. Methods Cell Biol. 2018; 143:147-156.View Related Profiles. PMID: 29310775.
  6. Bais MV, Kukuruzinska M, Trackman PC. Corrigendum to "Orthotopic non-metastatic and metastatic oral cancer mouse models" [Oral Oncol. 51(5) (2015) 476-482]. Oral Oncol. 2017 09; 72:201.View Related Profiles. PMID: 28743466.
  7. Kim D, Mecham RP, Trackman PC, Roy S. Downregulation of Lysyl Oxidase Protects Retinal Endothelial Cells From High Glucose-Induced Apoptosis. Invest Ophthalmol Vis Sci. 2017 May 01; 58(5):2725-2731.View Related Profiles. PMID: 28538980.
  8. Sánchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE. UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells. J Cell Biochem. 2017 Aug; 118(8):2347-2356.View Related Profiles. PMID: 28106301; DOI: 10.1002/jcb.25893;.
  9. Trackman PC, Saxena D, Bais MV. TGF-ß1- and CCN2-Stimulated Sirius Red Assay for Collagen Accumulation in Cultured Cells. Methods Mol Biol. 2017; 1489:481-485.View Related Profiles. PMID: 27734398.
  10. Trackman PC. Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer. Expert Opin Ther Targets. 2016 Aug; 20(8):935-45. PMID: 26848785; PMCID: PMC4988797; DOI: 10.1517/14728222.2016.1151003;.
Showing 10 of 109 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 107 publications over 33 distinct years, with a maximum of 7 publications in 2006 and 2007 and 2010 and 2015

Contact for Mentoring:

700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map

Trackman's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department